NCT07527195RecruitingPhase 1
Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)
Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 7 Apr 2026
- Start date
- 10 Apr 2026
- Primary completion date
- 28 Apr 2028
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Obesity
- NCT number
- NCT07527195
- EU CT number
- 2025-522920-28-00
- EudraCT number
- 2025-522920-28
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 100
- From 10 Apr 2026 to the primary completion date, 28 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any clinically significant body weight change (greater than or equal to \[\>=\] 5% self-reported change) or dieting attempts within 90 days before screening.
- Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist or a medication with GLP-1 activity within 90 days before screening.
Other
- Any leg amputations.
- Female participants who are not postmenopausal at screening.
Who the study is looking for
- Male or female.
- Age 50-70 years (both inclusive) at the time of signing the informed consent.
- Body Mass index (BMI) between 30.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening (V1).
- Excess body weight should be due to excess adipose tissue, as judged by the investigator.
- Participant has a wish to lose at least 25 percentage (%) of body weight within 52 weeks of treatment.
Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Region Midtjylland Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.